Celebrex Short Versus Long Therapy In Osteoarthritis Of The Knee

Pfizer

Status and phase: Completed; Phase 3

Conditions: Osteoarthritis,Knee

Treatments: Drug: Celebrex

Study type: Interventional

Funder types: Industry

Identifiers

NCT00137410

A3191091

635-IFL-0508-015

Details and patient eligibility

About

This is a phase III, multicentre, randomized, double blind, parallel-group, pilot study designed to compare a long term (12 weeks) versus a short term (2 weeks) treatment with celecoxib 200 mg/die in treatment and prevention of new flare in patients with osteoarthritis of the knee.

Sex: All

Ages: 50+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• diagnosis of OA of the knee according to the ACR Classification Criteria for osteoarthritis;
• patients in flare

Exclusion criteria

• any concomitant inflammatory rheumatic condition which may interfere with the assessment of OA
• clinical or radiological evidence of chondrocalcinosis

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Double Blind